Brief: Cognition Therapeutics Determined CFO Will Be Leaving Company As Of Aug. 12
27/07/2022 23:12
July 27 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS - ON JULY 21, 2022 CO DETERMINED
JAMES
O'BRIEN, CO'S CHIEF FINANCIAL OFFICER, WILL BE LEAVING COMPANY
AS OF AUGUST 12, 2022
* COGNITION THERAPEUTICS INC - ON JULY 25, 2022, BOARD
APPOINTED
ANDREW EINHORN AS INTERIM CHIEF FINANCIAL OFFICER
Source text for Eikon: [https://bit.ly/3PBwaPY]
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB